Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY03021 Phase I Study in Healthy Subjects
NCT07371065Phase 1Enrolling by invitation
- Sponsor
- Luye Pharma Group
- Start
- Oct 2025
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of toludesvenlafaxine in major depressive disorder (MDD) (2 arms), sponsored by Luye Pharma Group. Primary endpoint: Incidence of Adverse Events at 12 days. Started Oct 2025; status: enrolling by invitation.
02
Drugs
toludesvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07371065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07371065.